This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Urba, S. G. Articles by Schuller, D. E. Search for Related Content PubMed PubMed Citation Articles by Urba, S. G. Articles by Schuller, D. E. Social Bookmarking                            What's this?

Organ Preservation for Advanced Resectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial

From the University of Michigan Medical Center, Ann Arbor; Wayne State University Medical Center, Detroit, MI; Southwest Oncology Group Statistical Center, Seattle, WA; Eastern Virginia Medical School, Norfolk, VA; Cleveland Clinic Foundation, Cleveland; Ohio State University Medical Center, Columbus, OH; and University of Arkansas for Medical Science, Little Rock, AR

Address reprint requests to Southwest Oncology Group (SWOG-9451), Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217; e-mail: pubs{at}swog.org

PURPOSE: The Southwest Oncology Group designed a phase II trial for patients with base of tongue or hypopharyngeal cancer to evaluate the complete histologic response rate at the primary site after induction chemotherapy followed by chemoradiotherapy for responders. Secondary end points were the rate of organ preservation and the need for salvage surgery.

PATIENTS AND METHODS: Fifty-nine eligible patients were enrolled; 37 had base of tongue cancer, and 22 had hypopharynx cancer. Forty-two percent had stage III disease, and 58% had stage IV disease. Induction chemotherapy was two cycles of cisplatin 100 mg/m² and fluorouracil 1,000 mg/m²/d for 5 days. Patients who had a greater than 50% response at the primary site were treated with radiation 72Gy and concurrent cisplatin 100 mg/m² for three cycles. Patients with less than partial response at the primary had immediate salvage surgery.

RESULTS: Forty-five patients (76%) had a greater than 50% response at the primary after induction chemotherapy; 43 went on to receive definitive chemoradiotherapy. Thirty-two patients (54%) achieved a histologic complete response at the primary site, and an additional nine patients had a complete clinical response, but biopsy was not done. Seventy-five percent of patients did not require surgery at the primary tumor site. The 3-year overall survival was 64%. The 3-year progression-free survival with organ preservation was 52%.

CONCLUSION: Patients with base of tongue or hypopharyngeal cancer treated with this regimen of induction chemotherapy followed by definitive chemoradiotherapy have a good rate of organ preservation without compromise of survival.

Supported in part by the following Public Health Services Cooperative Agreement grants awarded by the National Cancer Institute’s Department of Health and Human Services: CA38926, CA32102, CA27057, CA14028, CA37981, CA58416, CA03096, CA58686, CA74647.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Eliason, A. Bowen, L. Hazard, and W. Samlowski Primary Treatment of Verrucous Carcinoma of the Penis With Fluorouracil, cis-Diamino-dichloro-platinum, and Radiation Therapy Arch Dermatol, August 1, 2009; 145(8): 950 - 952. [Full Text] [PDF]

				G. T. Wolf Tradition, Teamwork, and Tailored Treatment: Surgical Oncology in the Genomic Era Arch Otolaryngol Head Neck Surg, April 1, 2009; 135(4): 337 - 341. [Full Text] [PDF]

				S.-K. Tai, M.-H. Yang, L.-W. Wang, T.-L. Tsai, P.-Y. Chu, Y.-F. Wang, J.-L. Huang, and S.-Y. Chang Chemoradiotherapy Laryngeal Preservation for Advanced Hypopharyngeal Cancer Jpn. J. Clin. Oncol., August 11, 2008; (2008) hyn073v1. [Abstract] [Full Text] [PDF]

				F. P. Worden, B. Kumar, J. S. Lee, G. T. Wolf, K. G. Cordell, J. M.G. Taylor, S. G. Urba, A. Eisbruch, T. N. Teknos, D. B. Chepeha, et al. Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number J. Clin. Oncol., July 1, 2008; 26(19): 3138 - 3146. [Abstract] [Full Text] [PDF]

				M. Kawashima, H. Fujii, R. Hayashi, M. Tahara, K. Nasu, S. Arahira, and T. Ogino Influence of Delayed Tumor Clearance on Reliability of Complete Response Rate in Chemoradiotherapy for Head and Neck Cancer Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym072v1. [Abstract] [Full Text] [PDF]

				D. E. Schuller, E. Ozer, A. Agrawal, J. C. Grecula, C. A. Rhoades, and D. C. Young Multimodal Intensification Regimens for Advanced, Resectable, Previously Untreated Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx: A 12-Year Experience Arch Otolaryngol Head Neck Surg, April 1, 2007; 133(4): 320 - 326. [Abstract] [Full Text] [PDF]

				D. J. Adelstein and M. LeBlanc Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer? J. Clin. Oncol., June 10, 2006; 24(17): 2624 - 2628. [Abstract] [Full Text] [PDF]